Prevalence and correlates of experiencing drug-related discrimination among people who use drugs presenting at emergency department at high risk of opioid overdose

• Published in: Addictive behaviors reports Vol. 17; p. 100496
• Main Authors: Nolen, Shayla, Wilson, Taneisha, Jacka, Brendan P., Li, Yu, Beaudoin, Francesca L., Marshall, Brandon D.L.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.06.2023; Elsevier
• Subjects: Short Communication
• DOI: 10.1016/j.abrep.2023.100496
• ISSN: 2352-8532

•40.5% of PWUD reported drug-related discrimination in emergency departments.•PWUD who identified as women were more likely to report drug-related discrimination.•PWUD who identified as LGBQIA+ were also more likely to report discrimination in EDs. Our objective is to determine if specific sociodemographic characteristics were associated with perceived drug-related discrimination among people who use drugs (PWUD) presenting for care in the emergency department (ED). We conducted a secondary analysis of data from the Navigator trial, a randomized control trial of two behavioral interventions in the ED for people at risk of an opioid overdose. Participants included adult patients presenting to two Rhode Island EDs. Eligible participants included those high risk for an opioid overdose, resided or received most of their healthcare in Rhode Island, and were able to provide consent. The primary outcome of this analysis was self-reported feelings of drug-related discrimination by the medical community. The independent variables of interest included race/ethnicity, gender identity, and sexual orientation. Log-binomial multivariable regression models were constructed with all three independent variables of interest and a selection of sociodemographic covariates. Of 620 eligible participants, 251 (40.5%) reported ever experiencing drug-related discrimination in their lifetime. In the adjusted model, participants who identified as women and participants who identified as LGBQIA+ were more likely to report experiencing drug-related discrimination from the medical community in EDs. Racial/ethnic minority groups were less likely than White (non-Hispanic) participants to report drug-related discrimination. In this study population, White participants reported more drug-related discrimination than their minority counterparts, although female and LGBQIA+ patients reported more discrimination. Future studies should further assess the significance of these intersecting identities on self-reported discrimination. This knowledge could improve ED-based interventions, policies, and services for PWUD.